Polycystic ovary syndrome and insulin-resistant hyperinsulinemia

Journal of the American Academy of Dermatology

Volumn 45, Issue 3 SUPPL., 2001, Pages

  Rosenfield, R L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; LUTEINIZING HORMONE;

ANDROGEN BLOOD LEVEL; CONFERENCE PAPER; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE TYPE ALOPECIA; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STEROIDOGENESIS; THECA CELL;

EID: 0034858480     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.117430     Document Type: Conference Paper

References (64)

1. The polycystic ovary syndrome: Pathogenesis and treatment
2. Amenorrhea associated with bilateral polycystic ovaries
3. The polycystic ovary. I. Clinical and histologic features
4. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease
5. Polycystic ovary syndrome: A changing perspective
6. Insulin resistance in nonobese patients with polycystic ovary syndrome
7. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
8. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism
9. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome
10. Current concepts of polycystic ovary syndrome
11. Diagnostic criteria for polycystic ovary syndrome towards a rational approach
12. Detection of functional ovarian hyperandrogenism in women with androgen excess
13. Inappropriate gonadotropin secretion in polycystic ovary syndrome: Influence of adiposity
14. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
15. Gonadotrophin and gonadal steroid response to a dose of long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome
16. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome
17. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: Evidence from GnRH agonist and human chorionic gonadotropin stimulation testing
18. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries
19. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
20. Ovarian and adrenal function in polycystic ovary syndrome
21. Studies of the nature of 17-hydroxyprogesterone hyperresponsiveness to gonadotropin releasing hormone agonist challenge in functional ovarian hyperandrogenism
22. Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries
23. Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells
24. Clinical presentation of PCOS following development of an insulinoma: Case report
25. Correlation of hyperandrogenism with hyperinsulinemia in polycystic ovarian disease
26. Acanthosis nigricans, insulin action, and hyperandrogenism: Clinical, histological, and biochemical findings
27. Obesity, lipids, cardiovascular risk, and androgen excess
28. Insulin secretory defects in polycystic ovary syndrome: Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
29. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome
30. Regulation of beta-cell function in vivo: From health to disease
31. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
32. 17α-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss
33. Insulin-sensitising agents in polycystic-ovary syndrome
34. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
35. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome
36. Insulin-mediated pseudoacromegaly: Clinical and biochemical characterization of a syndrome of selective insulin resistance
37. Selective insulin resistance in the polycystic ovary syndrome
38. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states
39. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia
40. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system
41. Developmental changes in insulin action and secretion in childhood health and disease
42. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome
43. A direct effect of hyperinsulinemia on serum sex-hormone binding globulin levels in obese women with the polycystic ovary syndrome
44. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes
45. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity
46. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity
47. Systemic resistance to the antilipolytic effect of insulin in black and white women with visceral obesity
48. Insulin increases lipogenic enzyme activity in human adipocytes in primary culture
49. Non-insulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance
50. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness
51. Pilosebaceous physiology in relation to hirsutism and acne
52. The control of hair growth: An overview
53. Acne, hirsutism, and alopecia in adolescent girls
54. The relationship of mild hirsutism or acne in women to androgens
55. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?
56. Androgen receptor defects: Historical, clinical, and molecular perspectives
57. Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia
58. Steroid 5 alpha-reductase 2 deficiency
59. Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factorI from dermal papilla cells
60. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation
61. Anabolic and androgenic effect of testosterone on sexually immature boys and its dependency on growth hormone
62. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors
63. Diagnosis and therapy of hyperandrogenism
64. Role of hormones in pilosebaceous unit development